Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odevixibat in Alagille Syndrome (ASSERT-EXT)
NCT05035030Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Sep 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of odevixibat in Alagille syndrome (ALGS), sponsored by Ipsen. Started Sep 2021; status: active, not recruiting.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NCT05035030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035030.